The TLR-7 agonist, imiquimod (IMQ), has been frequently used to stimulate disease-mediated activation of this pathway in vivo in preclinical models of lupus and viral-mediated inflammation [27,28,29]. Here, TLR7 is linked to systemic lupus erythematosus.